<DOC>
	<DOC>NCT01530763</DOC>
	<brief_summary>This is a study of safety and effectiveness of ceftaroline fosamil in children with Community Acquired Bacterial Pneumonia receiving antibiotic therapy in the hospital.</brief_summary>
	<brief_title>Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)</brief_title>
	<detailed_description>To evaluate safety, effectiveness, pharmacokinetics and tolerance of ceftaroline fosamil in children who are initially hospitalized with Community Acquired Bacterial Pneumonia (CABP)</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Male or female, 2 months to &lt; 18 years old. Presence of CABP requiring hospitalization and IV antibacterial therapy Documented history of any hypersensitivity of allergic reaction to any Î²lactam antimicrobial. Confirmed or suspected infection with a pathogen known to be resistant to ceftriaxone. Confirmed or suspected respiratory tract infection attributed to sources other than CABP pathogens. Noninfectious causes of pulmonary infiltrates.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Infections</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Teflaro</keyword>
	<keyword>cephalosporin</keyword>
</DOC>